1 Market Overview

1.1 Product Overview and Scope of Targeted Drugs for NSCLC

1.2 Classification of Targeted Drugs for NSCLC by Type

1.2.1 Overview: Global Targeted Drugs for NSCLC Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Targeted Drugs for NSCLC Revenue Market Share by Type in 2021

1.2.3 Target EGFR

1.2.4 Target ALK

1.2.5 Target HER2

1.2.6 Target ROS1

1.2.7 Target BRAF

1.2.8 Target MEK

1.2.9 Target VEGFR2

1.2.10 Target VEGF

1.2.11 Target MET

1.3 Global Targeted Drugs for NSCLC Market by Application

1.3.1 Overview: Global Targeted Drugs for NSCLC Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Squamous Cell Carcinoma of NSCLC

1.3.3 Adenocarcinoma of NSCLC

1.3.4 Large Cell Carcinoma of NSCLC

1.4 Global Targeted Drugs for NSCLC Market Size & Forecast

1.5 Global Targeted Drugs for NSCLC Market Size and Forecast by Region

1.5.1 Global Targeted Drugs for NSCLC Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Targeted Drugs for NSCLC Market Size by Region, (2017-2022)

1.5.3 North America Targeted Drugs for NSCLC Market Size and Prospect (2017-2028)

1.5.4 Europe Targeted Drugs for NSCLC Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Targeted Drugs for NSCLC Market Size and Prospect (2017-2028)

1.5.6 South America Targeted Drugs for NSCLC Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Targeted Drugs for NSCLC Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Targeted Drugs for NSCLC Market Drivers

1.6.2 Targeted Drugs for NSCLC Market Restraints

1.6.3 Targeted Drugs for NSCLC Trends Analysis

2 Company Profiles

2.1 Allergan

2.1.1 Allergan Details

2.1.2 Allergan Major Business

2.1.3 Allergan Targeted Drugs for NSCLC Product and Solutions

2.1.4 Allergan Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Allergan Recent Developments and Future Plans

2.2 Amgen

2.2.1 Amgen Details

2.2.2 Amgen Major Business

2.2.3 Amgen Targeted Drugs for NSCLC Product and Solutions

2.2.4 Amgen Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Amgen Recent Developments and Future Plans

2.3 ARIAD Pharmaceuticals (Takeda)

2.3.1 ARIAD Pharmaceuticals (Takeda) Details

2.3.2 ARIAD Pharmaceuticals (Takeda) Major Business

2.3.3 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product and Solutions

2.3.4 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 ARIAD Pharmaceuticals (Takeda) Recent Developments and Future Plans

2.4 Beacon Pharma Limited

2.4.1 Beacon Pharma Limited Details

2.4.2 Beacon Pharma Limited Major Business

2.4.3 Beacon Pharma Limited Targeted Drugs for NSCLC Product and Solutions

2.4.4 Beacon Pharma Limited Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Beacon Pharma Limited Recent Developments and Future Plans

2.5 BeiGene

2.5.1 BeiGene Details

2.5.2 BeiGene Major Business

2.5.3 BeiGene Targeted Drugs for NSCLC Product and Solutions

2.5.4 BeiGene Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 BeiGene Recent Developments and Future Plans

2.6 Biocon

2.6.1 Biocon Details

2.6.2 Biocon Major Business

2.6.3 Biocon Targeted Drugs for NSCLC Product and Solutions

2.6.4 Biocon Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Biocon Recent Developments and Future Plans

2.7 Boehringer-Ingelheim

2.7.1 Boehringer-Ingelheim Details

2.7.2 Boehringer-Ingelheim Major Business

2.7.3 Boehringer-Ingelheim Targeted Drugs for NSCLC Product and Solutions

2.7.4 Boehringer-Ingelheim Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Boehringer-Ingelheim Recent Developments and Future Plans

2.8 Celgene Corporation

2.8.1 Celgene Corporation Details

2.8.2 Celgene Corporation Major Business

2.8.3 Celgene Corporation Targeted Drugs for NSCLC Product and Solutions

2.8.4 Celgene Corporation Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Celgene Corporation Recent Developments and Future Plans

2.9 Drug International Limted

2.9.1 Drug International Limted Details

2.9.2 Drug International Limted Major Business

2.9.3 Drug International Limted Targeted Drugs for NSCLC Product and Solutions

2.9.4 Drug International Limted Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Drug International Limted Recent Developments and Future Plans

2.10 Fujifilm Kyowa Kirin Biologics

2.10.1 Fujifilm Kyowa Kirin Biologics Details

2.10.2 Fujifilm Kyowa Kirin Biologics Major Business

2.10.3 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product and Solutions

2.10.4 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Fujifilm Kyowa Kirin Biologics Recent Developments and Future Plans

2.11 Genvio Pharma Limited

2.11.1 Genvio Pharma Limited Details

2.11.2 Genvio Pharma Limited Major Business

2.11.3 Genvio Pharma Limited Targeted Drugs for NSCLC Product and Solutions

2.11.4 Genvio Pharma Limited Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Genvio Pharma Limited Recent Developments and Future Plans

2.12 Hetero Drugs

2.12.1 Hetero Drugs Details

2.12.2 Hetero Drugs Major Business

2.12.3 Hetero Drugs Targeted Drugs for NSCLC Product and Solutions

2.12.4 Hetero Drugs Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Hetero Drugs Recent Developments and Future Plans

2.13 ImClone Systems ‎(Eli Lilly)

2.13.1 ImClone Systems ‎(Eli Lilly) Details

2.13.2 ImClone Systems ‎(Eli Lilly) Major Business

2.13.3 ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Product and Solutions

2.13.4 ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 ImClone Systems ‎(Eli Lilly) Recent Developments and Future Plans

2.14 Incepta Pharmaceuticals

2.14.1 Incepta Pharmaceuticals Details

2.14.2 Incepta Pharmaceuticals Major Business

2.14.3 Incepta Pharmaceuticals Targeted Drugs for NSCLC Product and Solutions

2.14.4 Incepta Pharmaceuticals Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 Incepta Pharmaceuticals Recent Developments and Future Plans

2.15 Mylan

2.15.1 Mylan Details

2.15.2 Mylan Major Business

2.15.3 Mylan Targeted Drugs for NSCLC Product and Solutions

2.15.4 Mylan Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.15.5 Mylan Recent Developments and Future Plans

2.16 Novartis

2.16.1 Novartis Details

2.16.2 Novartis Major Business

2.16.3 Novartis Targeted Drugs for NSCLC Product and Solutions

2.16.4 Novartis Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.16.5 Novartis Recent Developments and Future Plans

2.17 Pfizer

2.17.1 Pfizer Details

2.17.2 Pfizer Major Business

2.17.3 Pfizer Targeted Drugs for NSCLC Product and Solutions

2.17.4 Pfizer Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.17.5 Pfizer Recent Developments and Future Plans

2.18 Reliance Lifesciences

2.18.1 Reliance Lifesciences Details

2.18.2 Reliance Lifesciences Major Business

2.18.3 Reliance Lifesciences Targeted Drugs for NSCLC Product and Solutions

2.18.4 Reliance Lifesciences Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.18.5 Reliance Lifesciences Recent Developments and Future Plans

2.19 Roche

2.19.1 Roche Details

2.19.2 Roche Major Business

2.19.3 Roche Targeted Drugs for NSCLC Product and Solutions

2.19.4 Roche Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.19.5 Roche Recent Developments and Future Plans

2.20 AstraZeneca

2.20.1 AstraZeneca Details

2.20.2 AstraZeneca Major Business

2.20.3 AstraZeneca Targeted Drugs for NSCLC Product and Solutions

2.20.4 AstraZeneca Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.20.5 AstraZeneca Recent Developments and Future Plans

2.21 Cipla

2.21.1 Cipla Details

2.21.2 Cipla Major Business

2.21.3 Cipla Targeted Drugs for NSCLC Product and Solutions

2.21.4 Cipla Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.21.5 Cipla Recent Developments and Future Plans

2.22 Teva

2.22.1 Teva Details

2.22.2 Teva Major Business

2.22.3 Teva Targeted Drugs for NSCLC Product and Solutions

2.22.4 Teva Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.22.5 Teva Recent Developments and Future Plans

2.23 OSI Pharmaceuticals

2.23.1 OSI Pharmaceuticals Details

2.23.2 OSI Pharmaceuticals Major Business

2.23.3 OSI Pharmaceuticals Targeted Drugs for NSCLC Product and Solutions

2.23.4 OSI Pharmaceuticals Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.23.5 OSI Pharmaceuticals Recent Developments and Future Plans

2.24 Glenmark Pharmaceuticals

2.24.1 Glenmark Pharmaceuticals Details

2.24.2 Glenmark Pharmaceuticals Major Business

2.24.3 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Product and Solutions

2.24.4 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.24.5 Glenmark Pharmaceuticals Recent Developments and Future Plans

2.25 Natco Pharma

2.25.1 Natco Pharma Details

2.25.2 Natco Pharma Major Business

2.25.3 Natco Pharma Targeted Drugs for NSCLC Product and Solutions

2.25.4 Natco Pharma Targeted Drugs for NSCLC Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.25.5 Natco Pharma Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Targeted Drugs for NSCLC Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Targeted Drugs for NSCLC Players Market Share in 2021

3.2.2 Top 10 Targeted Drugs for NSCLC Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Targeted Drugs for NSCLC Players Head Office, Products and Services Provided

3.4 Targeted Drugs for NSCLC Mergers & Acquisitions

3.5 Targeted Drugs for NSCLC New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Targeted Drugs for NSCLC Revenue and Market Share by Type (2017-2022)

4.2 Global Targeted Drugs for NSCLC Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Targeted Drugs for NSCLC Revenue Market Share by Application (2017-2022)

5.2 Global Targeted Drugs for NSCLC Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Targeted Drugs for NSCLC Revenue by Type (2017-2028)

6.2 North America Targeted Drugs for NSCLC Revenue by Application (2017-2028)

6.3 North America Targeted Drugs for NSCLC Market Size by Country

6.3.1 North America Targeted Drugs for NSCLC Revenue by Country (2017-2028)

6.3.2 United States Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

6.3.3 Canada Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

6.3.4 Mexico Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Targeted Drugs for NSCLC Revenue by Type (2017-2028)

7.2 Europe Targeted Drugs for NSCLC Revenue by Application (2017-2028)

7.3 Europe Targeted Drugs for NSCLC Market Size by Country

7.3.1 Europe Targeted Drugs for NSCLC Revenue by Country (2017-2028)

7.3.2 Germany Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

7.3.3 France Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

7.3.5 Russia Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

7.3.6 Italy Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Targeted Drugs for NSCLC Revenue by Type (2017-2028)

8.2 Asia-Pacific Targeted Drugs for NSCLC Revenue by Application (2017-2028)

8.3 Asia-Pacific Targeted Drugs for NSCLC Market Size by Region

8.3.1 Asia-Pacific Targeted Drugs for NSCLC Revenue by Region (2017-2028)

8.3.2 China Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

8.3.3 Japan Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

8.3.4 South Korea Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

8.3.5 India Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

8.3.7 Australia Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Targeted Drugs for NSCLC Revenue by Type (2017-2028)

9.2 South America Targeted Drugs for NSCLC Revenue by Application (2017-2028)

9.3 South America Targeted Drugs for NSCLC Market Size by Country

9.3.1 South America Targeted Drugs for NSCLC Revenue by Country (2017-2028)

9.3.2 Brazil Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

9.3.3 Argentina Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Targeted Drugs for NSCLC Revenue by Type (2017-2028)

10.2 Middle East & Africa Targeted Drugs for NSCLC Revenue by Application (2017-2028)

10.3 Middle East & Africa Targeted Drugs for NSCLC Market Size by Country

10.3.1 Middle East & Africa Targeted Drugs for NSCLC Revenue by Country (2017-2028)

10.3.2 Turkey Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

10.3.4 UAE Targeted Drugs for NSCLC Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Targeted Drugs for NSCLC Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Targeted Drugs for NSCLC Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Targeted Drugs for NSCLC Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Targeted Drugs for NSCLC Revenue (USD Million) by Region (2017-2022)

Table 5. Global Targeted Drugs for NSCLC Revenue Market Share by Region (2023-2028)

Table 6. Allergan Corporate Information, Head Office, and Major Competitors

Table 7. Allergan Major Business

Table 8. Allergan Targeted Drugs for NSCLC Product and Solutions

Table 9. Allergan Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Amgen Corporate Information, Head Office, and Major Competitors

Table 11. Amgen Major Business

Table 12. Amgen Targeted Drugs for NSCLC Product and Solutions

Table 13. Amgen Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. ARIAD Pharmaceuticals (Takeda) Corporate Information, Head Office, and Major Competitors

Table 15. ARIAD Pharmaceuticals (Takeda) Major Business

Table 16. ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product and Solutions

Table 17. ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Beacon Pharma Limited Corporate Information, Head Office, and Major Competitors

Table 19. Beacon Pharma Limited Major Business

Table 20. Beacon Pharma Limited Targeted Drugs for NSCLC Product and Solutions

Table 21. Beacon Pharma Limited Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. BeiGene Corporate Information, Head Office, and Major Competitors

Table 23. BeiGene Major Business

Table 24. BeiGene Targeted Drugs for NSCLC Product and Solutions

Table 25. BeiGene Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Biocon Corporate Information, Head Office, and Major Competitors

Table 27. Biocon Major Business

Table 28. Biocon Targeted Drugs for NSCLC Product and Solutions

Table 29. Biocon Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Boehringer-Ingelheim Corporate Information, Head Office, and Major Competitors

Table 31. Boehringer-Ingelheim Major Business

Table 32. Boehringer-Ingelheim Targeted Drugs for NSCLC Product and Solutions

Table 33. Boehringer-Ingelheim Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Celgene Corporation Corporate Information, Head Office, and Major Competitors

Table 35. Celgene Corporation Major Business

Table 36. Celgene Corporation Targeted Drugs for NSCLC Product and Solutions

Table 37. Celgene Corporation Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Drug International Limted Corporate Information, Head Office, and Major Competitors

Table 39. Drug International Limted Major Business

Table 40. Drug International Limted Targeted Drugs for NSCLC Product and Solutions

Table 41. Drug International Limted Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Fujifilm Kyowa Kirin Biologics Corporate Information, Head Office, and Major Competitors

Table 43. Fujifilm Kyowa Kirin Biologics Major Business

Table 44. Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product and Solutions

Table 45. Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Genvio Pharma Limited Corporate Information, Head Office, and Major Competitors

Table 47. Genvio Pharma Limited Major Business

Table 48. Genvio Pharma Limited Targeted Drugs for NSCLC Product and Solutions

Table 49. Genvio Pharma Limited Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Hetero Drugs Corporate Information, Head Office, and Major Competitors

Table 51. Hetero Drugs Major Business

Table 52. Hetero Drugs Targeted Drugs for NSCLC Product and Solutions

Table 53. Hetero Drugs Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. ImClone Systems ‎(Eli Lilly) Corporate Information, Head Office, and Major Competitors

Table 55. ImClone Systems ‎(Eli Lilly) Major Business

Table 56. ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Product and Solutions

Table 57. ImClone Systems ‎(Eli Lilly) Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Incepta Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 59. Incepta Pharmaceuticals Major Business

Table 60. Incepta Pharmaceuticals Targeted Drugs for NSCLC Product and Solutions

Table 61. Incepta Pharmaceuticals Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. Mylan Corporate Information, Head Office, and Major Competitors

Table 63. Mylan Major Business

Table 64. Mylan Targeted Drugs for NSCLC Product and Solutions

Table 65. Mylan Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 66. Novartis Corporate Information, Head Office, and Major Competitors

Table 67. Novartis Major Business

Table 68. Novartis Targeted Drugs for NSCLC Product and Solutions

Table 69. Novartis Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 70. Pfizer Corporate Information, Head Office, and Major Competitors

Table 71. Pfizer Major Business

Table 72. Pfizer Targeted Drugs for NSCLC Product and Solutions

Table 73. Pfizer Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 74. Reliance Lifesciences Corporate Information, Head Office, and Major Competitors

Table 75. Reliance Lifesciences Major Business

Table 76. Reliance Lifesciences Targeted Drugs for NSCLC Product and Solutions

Table 77. Reliance Lifesciences Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 78. Roche Corporate Information, Head Office, and Major Competitors

Table 79. Roche Major Business

Table 80. Roche Targeted Drugs for NSCLC Product and Solutions

Table 81. Roche Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 82. AstraZeneca Corporate Information, Head Office, and Major Competitors

Table 83. AstraZeneca Major Business

Table 84. AstraZeneca Targeted Drugs for NSCLC Product and Solutions

Table 85. AstraZeneca Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 86. Cipla Corporate Information, Head Office, and Major Competitors

Table 87. Cipla Major Business

Table 88. Cipla Targeted Drugs for NSCLC Product and Solutions

Table 89. Cipla Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 90. Teva Corporate Information, Head Office, and Major Competitors

Table 91. Teva Major Business

Table 92. Teva Targeted Drugs for NSCLC Product and Solutions

Table 93. Teva Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 94. OSI Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 95. OSI Pharmaceuticals Major Business

Table 96. OSI Pharmaceuticals Targeted Drugs for NSCLC Product and Solutions

Table 97. OSI Pharmaceuticals Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 98. Glenmark Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 99. Glenmark Pharmaceuticals Major Business

Table 100. Glenmark Pharmaceuticals Targeted Drugs for NSCLC Product and Solutions

Table 101. Glenmark Pharmaceuticals Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 102. Natco Pharma Corporate Information, Head Office, and Major Competitors

Table 103. Natco Pharma Major Business

Table 104. Natco Pharma Targeted Drugs for NSCLC Product and Solutions

Table 105. Natco Pharma Targeted Drugs for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 106. Global Targeted Drugs for NSCLC Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 107. Global Targeted Drugs for NSCLC Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 108. Breakdown of Targeted Drugs for NSCLC by Company Type (Tier 1, Tier 2 and Tier 3)

Table 109. Targeted Drugs for NSCLC Players Head Office, Products and Services Provided

Table 110. Targeted Drugs for NSCLC Mergers & Acquisitions in the Past Five Years

Table 111. Targeted Drugs for NSCLC New Entrants and Expansion Plans

Table 112. Global Targeted Drugs for NSCLC Revenue (USD Million) by Type (2017-2022)

Table 113. Global Targeted Drugs for NSCLC Revenue Share by Type (2017-2022)

Table 114. Global Targeted Drugs for NSCLC Revenue Forecast by Type (2023-2028)

Table 115. Global Targeted Drugs for NSCLC Revenue by Application (2017-2022)

Table 116. Global Targeted Drugs for NSCLC Revenue Forecast by Application (2023-2028)

Table 117. North America Targeted Drugs for NSCLC Revenue by Type (2017-2022) & (USD Million)

Table 118. North America Targeted Drugs for NSCLC Revenue by Type (2023-2028) & (USD Million)

Table 119. North America Targeted Drugs for NSCLC Revenue by Application (2017-2022) & (USD Million)

Table 120. North America Targeted Drugs for NSCLC Revenue by Application (2023-2028) & (USD Million)

Table 121. North America Targeted Drugs for NSCLC Revenue by Country (2017-2022) & (USD Million)

Table 122. North America Targeted Drugs for NSCLC Revenue by Country (2023-2028) & (USD Million)

Table 123. Europe Targeted Drugs for NSCLC Revenue by Type (2017-2022) & (USD Million)

Table 124. Europe Targeted Drugs for NSCLC Revenue by Type (2023-2028) & (USD Million)

Table 125. Europe Targeted Drugs for NSCLC Revenue by Application (2017-2022) & (USD Million)

Table 126. Europe Targeted Drugs for NSCLC Revenue by Application (2023-2028) & (USD Million)

Table 127. Europe Targeted Drugs for NSCLC Revenue by Country (2017-2022) & (USD Million)

Table 128. Europe Targeted Drugs for NSCLC Revenue by Country (2023-2028) & (USD Million)

Table 129. Asia-Pacific Targeted Drugs for NSCLC Revenue by Type (2017-2022) & (USD Million)

Table 130. Asia-Pacific Targeted Drugs for NSCLC Revenue by Type (2023-2028) & (USD Million)

Table 131. Asia-Pacific Targeted Drugs for NSCLC Revenue by Application (2017-2022) & (USD Million)

Table 132. Asia-Pacific Targeted Drugs for NSCLC Revenue by Application (2023-2028) & (USD Million)

Table 133. Asia-Pacific Targeted Drugs for NSCLC Revenue by Region (2017-2022) & (USD Million)

Table 134. Asia-Pacific Targeted Drugs for NSCLC Revenue by Region (2023-2028) & (USD Million)

Table 135. South America Targeted Drugs for NSCLC Revenue by Type (2017-2022) & (USD Million)

Table 136. South America Targeted Drugs for NSCLC Revenue by Type (2023-2028) & (USD Million)

Table 137. South America Targeted Drugs for NSCLC Revenue by Application (2017-2022) & (USD Million)

Table 138. South America Targeted Drugs for NSCLC Revenue by Application (2023-2028) & (USD Million)

Table 139. South America Targeted Drugs for NSCLC Revenue by Country (2017-2022) & (USD Million)

Table 140. South America Targeted Drugs for NSCLC Revenue by Country (2023-2028) & (USD Million)

Table 141. Middle East & Africa Targeted Drugs for NSCLC Revenue by Type (2017-2022) & (USD Million)

Table 142. Middle East & Africa Targeted Drugs for NSCLC Revenue by Type (2023-2028) & (USD Million)

Table 143. Middle East & Africa Targeted Drugs for NSCLC Revenue by Application (2017-2022) & (USD Million)

Table 144. Middle East & Africa Targeted Drugs for NSCLC Revenue by Application (2023-2028) & (USD Million)

Table 145. Middle East & Africa Targeted Drugs for NSCLC Revenue by Country (2017-2022) & (USD Million)

Table 146. Middle East & Africa Targeted Drugs for NSCLC Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Targeted Drugs for NSCLC Picture

Figure 2. Global Targeted Drugs for NSCLC Revenue Market Share by Type in 2021

Figure 3. Target EGFR

Figure 4. Target ALK

Figure 5. Target HER2

Figure 6. Target ROS1

Figure 7. Target BRAF

Figure 8. Target MEK

Figure 9. Target VEGFR2

Figure 10. Target VEGF

Figure 11. Target MET

Figure 12. Targeted Drugs for NSCLC Revenue Market Share by Application in 2021

Figure 13. Squamous Cell Carcinoma of NSCLC Picture

Figure 14. Adenocarcinoma of NSCLC Picture

Figure 15. Large Cell Carcinoma of NSCLC Picture

Figure 16. Global Targeted Drugs for NSCLC Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 17. Global Targeted Drugs for NSCLC Revenue and Forecast (2017-2028) & (USD Million)

Figure 18. Global Targeted Drugs for NSCLC Revenue Market Share by Region (2017-2028)

Figure 19. Global Targeted Drugs for NSCLC Revenue Market Share by Region in 2021

Figure 20. North America Targeted Drugs for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)

Figure 21. Europe Targeted Drugs for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)

Figure 22. Asia-Pacific Targeted Drugs for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)

Figure 23. South America Targeted Drugs for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)

Figure 24. Middle East and Africa Targeted Drugs for NSCLC Revenue (USD Million) and Growth Rate (2017-2028)

Figure 25. Targeted Drugs for NSCLC Market Drivers

Figure 26. Targeted Drugs for NSCLC Market Restraints

Figure 27. Targeted Drugs for NSCLC Market Trends

Figure 28. Allergan Recent Developments and Future Plans

Figure 29. Amgen Recent Developments and Future Plans

Figure 30. ARIAD Pharmaceuticals (Takeda) Recent Developments and Future Plans

Figure 31. Beacon Pharma Limited Recent Developments and Future Plans

Figure 32. BeiGene Recent Developments and Future Plans

Figure 33. Biocon Recent Developments and Future Plans

Figure 34. Boehringer-Ingelheim Recent Developments and Future Plans

Figure 35. Celgene Corporation Recent Developments and Future Plans

Figure 36. Drug International Limted Recent Developments and Future Plans

Figure 37. Fujifilm Kyowa Kirin Biologics Recent Developments and Future Plans

Figure 38. Genvio Pharma Limited Recent Developments and Future Plans

Figure 39. Hetero Drugs Recent Developments and Future Plans

Figure 40. ImClone Systems ‎(Eli Lilly) Recent Developments and Future Plans

Figure 41. Incepta Pharmaceuticals Recent Developments and Future Plans

Figure 42. Mylan Recent Developments and Future Plans

Figure 43. Novartis Recent Developments and Future Plans

Figure 44. Pfizer Recent Developments and Future Plans

Figure 45. Reliance Lifesciences Recent Developments and Future Plans

Figure 46. Roche Recent Developments and Future Plans

Figure 47. AstraZeneca Recent Developments and Future Plans

Figure 48. Cipla Recent Developments and Future Plans

Figure 49. Teva Recent Developments and Future Plans

Figure 50. OSI Pharmaceuticals Recent Developments and Future Plans

Figure 51. Glenmark Pharmaceuticals Recent Developments and Future Plans

Figure 52. Natco Pharma Recent Developments and Future Plans

Figure 53. Global Targeted Drugs for NSCLC Revenue Share by Players in 2021

Figure 54. Targeted Drugs for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 55. Global Top 3 Players Targeted Drugs for NSCLC Revenue Market Share in 2021

Figure 56. Global Top 10 Players Targeted Drugs for NSCLC Revenue Market Share in 2021

Figure 57. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 58. Global Targeted Drugs for NSCLC Revenue Share by Type in 2021

Figure 59. Global Targeted Drugs for NSCLC Market Share Forecast by Type (2023-2028)

Figure 60. Global Targeted Drugs for NSCLC Revenue Share by Application in 2021

Figure 61. Global Targeted Drugs for NSCLC Market Share Forecast by Application (2023-2028)

Figure 62. North America Targeted Drugs for NSCLC Sales Market Share by Type (2017-2028)

Figure 63. North America Targeted Drugs for NSCLC Sales Market Share by Application (2017-2028)

Figure 64. North America Targeted Drugs for NSCLC Revenue Market Share by Country (2017-2028)

Figure 65. United States Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. Canada Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. Mexico Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Europe Targeted Drugs for NSCLC Sales Market Share by Type (2017-2028)

Figure 69. Europe Targeted Drugs for NSCLC Sales Market Share by Application (2017-2028)

Figure 70. Europe Targeted Drugs for NSCLC Revenue Market Share by Country (2017-2028)

Figure 71. Germany Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 72. France Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 73. United Kingdom Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. Russia Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Italy Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Asia-Pacific Targeted Drugs for NSCLC Sales Market Share by Type (2017-2028)

Figure 77. Asia-Pacific Targeted Drugs for NSCLC Sales Market Share by Application (2017-2028)

Figure 78. Asia-Pacific Targeted Drugs for NSCLC Revenue Market Share by Region (2017-2028)

Figure 79. China Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. Japan Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. South Korea Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 82. India Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 83. Southeast Asia Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 84. Australia Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 85. South America Targeted Drugs for NSCLC Sales Market Share by Type (2017-2028)

Figure 86. South America Targeted Drugs for NSCLC Sales Market Share by Application (2017-2028)

Figure 87. South America Targeted Drugs for NSCLC Revenue Market Share by Country (2017-2028)

Figure 88. Brazil Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 89. Argentina Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 90. Middle East and Africa Targeted Drugs for NSCLC Sales Market Share by Type (2017-2028)

Figure 91. Middle East and Africa Targeted Drugs for NSCLC Sales Market Share by Application (2017-2028)

Figure 92. Middle East and Africa Targeted Drugs for NSCLC Revenue Market Share by Country (2017-2028)

Figure 93. Turkey Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 94. Saudi Arabia Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 95. UAE Targeted Drugs for NSCLC Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 96. Methodology

Figure 97. Research Process and Data Source